

CORRESPONDENCE

Open Access



# CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

Xinyuan Liu<sup>1†</sup>, Juanjuan Zhao<sup>2†</sup>, Xiangqian Guo<sup>1</sup> and Yongping Song<sup>2\*</sup>

## Abstract

Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20<sup>+</sup> NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).

**Keywords** Non-Hodgkin's lymphoma, Bispecific antibody, CD20, CD3, EPCORE NHL-1

## To the editor

Several CD20 × CD3 bispecific antibodies (bsAbs) have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20<sup>+</sup> NHL cells in clinical trials. Mosunetuzumab (Mosun), epcoritamab (Epcor) and glofitamab (Glofit) have been approved recently for refractory/relapsed (R/R) B-cell NHL therapy. We summarized several latest reports on CD20 × CD3 bsAbs from the ASCO 2023 annual meeting.

## Properties of CD20 × CD3 bsAbs

Glofit is a full-length IgG1 bsAb with a 2:1 molecular configuration of anti-CD20 and anti-CD3 (Table 1). The Fc of Glofit has a PG LALA mutation, resulting in the loss of the Fc-FcγRs interaction while retaining its binding ability to FcRn [1]. This particular structure possesses a longer half-life of 10 days when compared to earlier generation of bsAbs. Glofit is currently being investigated as a single agent and in combination regimens [2–4].

Mosun is a fully humanized IgG1 bsAb (Table 1). Mosun was administered as a fixed-duration regimen with step-up dosing to minimize cytokine release syndrome (CRS). The intravenous (IV) formulation has been approved, while subcutaneous (SC) Mosun is still in trials [5]. Mosun has been evaluated in clinical trials as a monotherapy or in combination regimens for the treatment of B-cell NHL [6–8].

Epcor is another IgG1 bsAb. It was designed to bind to a unique epitope on CD20 antigen, allowing co-binding of other anti-CD20 agents (Table 1) [5]. Compared with IV administration, SC Epcor (also known as GEN3013) demonstrated comparable bioavailability and B-cell depletion in cynomolgus monkeys [9].

<sup>†</sup>Xinyuan Liu and Juanjuan Zhao have contributed equally to this work.

\*Correspondence:  
Yongping Song  
songyp@zzu.edu.cn

<sup>1</sup> Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng 475004, Henan, China

<sup>2</sup> Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China



**Table 1** Properties of CD20×CD3 bispecific antibodies

Agent	Glofitamab	Mosunetuzumab	Epcoritamab
Length	Full-length IgG1	Fully humanized Full-length IgG1	Full-length IgG1
Configuration	Anti-CD20: anti-CD3 = 2:1	Anti-CD20: anti-CD3 = 1:1	Anti-CD20: anti-CD3 = 1:1
Fc mutation	PG LALA	N297	L234F, L235E, and D265A
Administration	IV	SC/IV	SC
Dosing	Step-wise	Step-wise	Step-wise
Depleting of B cells prior to bsAb	Yes	No	No
Combined with CD20 mAbs	Yes	No	Yes
References	[1, 4]	[5, 6]	[5, 9]

bsAb, bispecific antibody; Epcor, epcoritamab; Glofit, glofitamab; IV, intravenous; Mosun, Mosunetuzumab; SC, subcutaneous

**Efficacies of CD20 × CD3 bsAbs as a single agent**

In a phase II clinical trial for patients (pts) with R/R large B cell lymphoma (LBCL), obinutuzumab was administered prior to Glofit monotherapy to first reduce the tumor load [2, 4]. Glofit was given at a step-up dosing regimen. In the latest update, the complete response (CR) and overall response rates (ORR) were 38% and 59%, respectively, with a median follow-up (mFU) of 20.1 months (m) (Table 2). Notably, prior CAR T cell therapy did not adversely affect ORR. The

median duration of CR was 24.1 m [95% CI: 19.8–not reached (NR)]. Among pts who received doses lower than recommended but ≥ 10 mg, the CR duration was extended to 30.1 m. The 18-m overall survival (OS) rate was 41%. CRS was the most frequently reported adverse event (AE). Glofit was recently approved for R/R LBCL.

In the EPCORE NHL-1 trial for R/R LBCL, single-agent Epcor was administered with a step-wise dosing regimen [10]. The CR and ORR were 39.5% and 63.1%, respectively (Table 2). Median OS was 18.5 m. CRS

**Table 2** 2023 ASCO updates from clinical trials of CD20×CD3 bispecific antibodies for lymphoma therapy

Regimen	Epcor	Glofit	Epcor + R-CHOP	Glofit + Pola-R-CHP	Epcor + R <sup>2</sup>
Lymphoma	R/R LBCL	R/R LBCL	1L high-risk DLBCL	1L DLBCL	R/R FL
Pts	157	154	47	24	109
mFU	20 m (range: 0.3+–28.2)	20.1 m (range: 0–32)	11.5 m (range: 0.8–15.5)	5.1 m (range: 3–8)	8.8 m (range: 1.2–18.5)
ORR	63.1%	59%	100%	100%	97%
CR/CMR	CR: 39.5%	CR: 38%	CMR: 76%	CMR: 76.5%	CMR: 86%
mDoCR	20.8 m	24.1 m (95% CI 19.8–NR)	NR	NR	NR
PFS	87.2% at 1 year in pts with a CR	80% at 1 year in pts with a CR at EOT	NR	NR	NR
OS	mOS: 18.5 m (95% CI 11.7–NR)	41% (18-m) (95% CI 32.1–49.3)	NR	NR	NR
CRS	51%	64%	60%	13%	48%
G1–2	48%	60%	57%	13%	46%
G ≥ 3	3%	4%	2%	0	2%
NAE/ICANS	ICANS: 6%	NA	ICANS: 2%	NAE: 46%	ICANS: 2%
G1–2	6%		2%	42%	2%
G ≥ 3	1%		0	4%	0%
Clinical trial number	NCT03625037	NCT03075696	NCT04663347	NCT03467373	NCT04663347
References	[10]	[4]	[11]	[3]	[12]

CMR, complete metabolic response; CR, complete response; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; EOT: end of treatment; Epcor, epcoritamab; FL, follicular lymphoma; G: grade; Glofit, glofitamab; ICANS, immune effector cell-associated neurotoxicity syndrome; m, months; mDoCR, median duration of CR; mFU, median follow-up; mOS: median OS; Mosun, Mosunetuzumab; NA: not available; NAE, neurological adverse events; NR, not reached; ORR, overall response rate; OS, overall survival; PFS: progression-free survival; Pola, polatuzumab vedotin; Pts, patients; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R/R, relapsed/refractory; 1L, 1 line

occurred in 51% of pts, and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 6% of pts. Epcor was recently approved for R/R LBCL.

### Efficacies of CD20 × CD3 bsAbs in combination regimens

In the EPCORE NHL-2 trial, Epcor was combined with R-CHOP in adults with untreated high-risk DLBCL [11]. In the latest report, 47 pts had received Epcor 48 mg + R-CHOP with a mFU of 11.5 m (Table 2). All pts achieved a response (100%), and 76% achieved a complete metabolic response (CMR). The CMR occurred in 82% double/triple-hit pts. CRS occurred in 60% of pts, and 1 pt experienced ICANS.

In the EPCORE NHL-2 trial, SC Epcor was combined with R + lenalidomide in treating R/R follicular lymphoma (FL) [12]. One hundred and nine pts were treated with a mFU of 8.8 m. The CMR and ORR were 86% and 97%, respectively ( $n=101$ ) (Table 2). CRS occurred in 48% of pts, while 2 pts developed ICANS.

Glofit was employed in combination with polatuzumab vedotin (Pola) plus R-CHP for untreated DLBCL pts, with Pola-R-CHP given on Day 1 of each cycle (C) and Glofit administered in C2–C6 at a step-up dosing [3]. The CMR and ORR occurred in 76.5% and 100% of the 24 enrolled pts after a mFU of 5.1 m (Table 2). CRS and neurological AEs occurred in 13% and 46% pts, respectively.

In addition to the above trials, several clinical trials on CD20 × CD3 bsAbs in combination regimens are enrolling now. These include SC Mosun + IV Pola in pts with R/R NHL [8], SC Mosun with lenalidomide augmentation in pts with untreated FL and marginal zone lymphoma [7], and SC Epcor + R-CHOP in pts with newly diagnosed DLBCL [13].

In summary, Mosun, Epcor and Glofit have been approved recently for R/R B-cell NHL therapy. SC administration of Epcor offers convenience. CD20 × CD3 bsAbs in combination regimens are in clinical trials.

### Abbreviations

AE	Adverse events
ASCO	American Society of Clinical Oncology
bsAb	Bispecific antibody
CMR	Complete metabolic response
CR	Complete response
CRS	Cytokine release syndrome
DLBCL	Diffuse large B-cell lymphoma
Epcor	Epcoritamab
FL	Follicular lymphoma
Glofit	Glofitamab
ICANS	Immune effector cell-associated neurotoxicity syndrome
IV	Intravenous
m	Months
mDoCR	Median duration of CR
mFU	Median follow-up
Mosun	Mosunetuzumab
NHL	Non-Hodgkin lymphoma

NR	Not reached
ORR	Overall response rate
OS	Overall survival
Pola	Polatuzumab vedotin
pts	Patients
R-CHOP	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
R/R	Relapsed/refractory
SC	Subcutaneous
1L	1 Line

### Author contributions

YPS designed the study. XYL and JJZ drafted the manuscript and prepared the tables. All authors participated in the process of drafting and revising the manuscript. All authors read and approved the final manuscript.

### Funding

The study is supported by the Major Project of Henan Medical Science and Technology Research Plan (SBGJ202101007) and the First Affiliated Hospital of Zhengzhou University.

### Availability of data and materials

The material supporting the conclusion of this study has been included within the article.

### Declarations

#### Ethics approval and consent to participate

This is not applicable for this summary.

#### Consent for publication

This is not applicable for this summary.

#### Competing interests

The authors have no relevant competing interests.

Received: 10 June 2023 Accepted: 26 July 2023

Published online: 03 August 2023

### References

- Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Husser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umana P. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. *Clin Cancer Res*. 2018;24(19):4785–97.
- Wang C, Liu Y. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH annual meeting. *J Hematol Oncol*. 2023;16(1):20.
- Dickinson M, Viardot A, Marks R, Topp MS, Morschhauser F, Jacobs B, Tani M, Bosch F, Esteban D, Cordoba R, Kaufman D, Wu C, Humphrey K, Baumlin P, Barrett M, Qayum N, Pinto A. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study. *J Clin Oncol*. 2023;41(16\_suppl):7549–7549.
- Falchi L, Carlo-Stella C, Morschhauser F, Hutchings M, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody J, Leppä S, Mulvihill E, Lundberg L, Relf J, Xie Y, Bottos A, Humphrey K, Dickinson M. Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. *J Clin Oncol*. 2023;41(16\_suppl):7550–7550.
- Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. *Curr Treat Opt Oncol*. 2022;23(2):155–70.
- Cao Y, Marcucci EC, Budde LE. Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting. *J Hematol Oncol*. 2023;16(1):69.
- Olszewski AJ, Huntington SF, Ollila T, Pelcovits A, McMahon JB, Yakirevich I, Sturtevant A, Chorzalska A, Morgan J, Dubielecka P. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy

- for follicular (FL) and marginal zone lymphoma (MZL). *J Clin Oncol.* 2023;41(16\_suppl):TPS7588–TPS7588.
8. Westin J, Olszewski AJ, Fogliatto L, Kim WS, Shin H-J, Jeon Y-W, Nora-setthada L, Pavlovsky A, Rego E, Wu H, Yin S, Batlevi CL, Pham S, Penuel EM, Jing J, Wei MC, Budde LE. SUNMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatumumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *J Clin Oncol.* 2023;41(16\_suppl):TPS7586–TPS7586.
  9. Lugtenburg P, Mous R, Clausen MR, Chamuleau MED, Johnson P, Linton K, Rule S, Oliveri RS, DeMarco D, Hiemstra IH, Chen G, Azaryan A, Gupta M, Ahmadi T, Hutchings M. First-in-human, phase 1/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody®-CD3xCD20) in B-cell non-Hodgkin lymphomas. *Blood.* 2019;134(Supplement\_1):758–758.
  10. Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, Cunningham D, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon MLM, Feldman TA, Linton KM, Sureda A, Hutchings M, Cota Stirner M, Sacchi M, Thieblemont C. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial. *J Clin Oncol.* 2023;41(16\_suppl):7525–7525.
  11. Falchi L, Clausen M, Offner F, de Vos S, Brody J, Linton KM, Snauwaert S, Cordoba R, Wu J, Bykhovski I, Wang L, Rana A, Belada D. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: updated EPCORE NHL-2 data. *J Clin Oncol.* 2023;41(16\_suppl):7519–7519.
  12. Merryman R, Belada D, Sureda A, Leppä S, Vermaat JSP, Holte H, Hutchings M, Lugtenburg P, de Vos S, Abrisqueta P, Nijland M, Christensen JH, Wahlin BE, Linton KM, Wang L, Abbas A, Rana A, Quadri S, Falchi L. Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. *J Clin Oncol.* 2023;41(16\_suppl):7506–7506.
  13. Sehn LH, Chamuleau M, Lenz G, Clausen M, Haioun C, Izutsu K, Davies AJJ, Zhu J, Oki T, Szafer-Glusman E, Conlon R, Chiou H, Ipe D, Elliott B, Wu J, Salles GA. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2. *J Clin Oncol.* 2023;41(16\_suppl):TPS7592–TPS7592.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

